

Method Development, Validation and Force Degradation Stability Study of Olanzapine by UV-VIS Spectroscopy

Meenu Chaudhary*, Praveen Kumar¹, Anjali Gusain²

School of Pharmaceutical Sciences,
Shri Guru Ram Rai University, Dehradun, India

Abstract: A simple, unique and dependable UV-VIS spectrophotometric method used to be as soon as developed for the estimation of Olanzapine in bulk and pharmaceutical dosage forms. Water: Hydrochloric acid (9:1) was chosen as the solvent system. The λ_{max} was discovered to be 257 nm and the response linear in the range of 2-12 µg/ml. The regression equation of the calibration format and correlation coefficient had been found to be $Y = 0.0779 + 0.002X$ and 1.0 respectively. The %RSD values for each intraday and interday precision had been less than 1% the recovery of the drug from the pattern was once in precise range.

The proposed approach used to be validated for accuracy, precision, robustness, ruggedness, LOD and LOQ whilst estimating the commercial components there was no interference of excipients and other additives. The proposed approach for balance find out about suggests that there was considerable degradation located in stress circumstance of Olanzapine. Forced degradation research (stress testing) are very necessary tool in pharmaceutical look up and development to predict long-term stability. Stress studies need to be carried out in approach improvement to understand drug behavior however also can be carried out with approach validation for regulatory filling predict stability and measure impurities.

Key words: Olanzapine, UV-VIS Spectrophotometric, validation Study and Force Degradation study.

1. INTRODUCTION

A simple, special and reliable UV-VIS spectrophotometric method was once developed for the estimation of Olanzapine in bulk and pharmaceutical dosage forms. Water: Hydrochloric acid (9:1) was chosen as the solvent system. The λ_{max} used to be found to be 257 nm and the response linear. Drug balance refers to the capacity of the drug substance or product to continue to be within hooked up specification of identification, strength, fine and purity in a detailed period of time. Stability is formally defined as the time laps for the duration of which the drug product retains the equal houses characteristics that is proposed at the time of manufacture. The balance of the product is expressed as the expiry duration or technically as shelf lifestyles. [1,2]

Objective of the Stability Study:

The guidelines for stability study are given by ICH: [3,4]

Q1A (R2): Stability testing of new drug substance and products

Q1B: Stability testing: photo stability testing of new drug substance and products

Q1C: Stability testing of new dosage forms

Q1D: Bracketing and matrixing design for stability testing of new drug substances and products

Q1E: Evaluation of stability studies.

Q1F: Stability Data Package for Registration Applications in Climatic Zones III and IV

2. MATERIALS AND METHODS

Materials which are used for study of validation and force degradation study of olanzapine are given as well as following.

Table 1.1: - List of Chemicals used for preparation of Olanzapine

| S.No. | Drug / Excipient / Solvent | Manufacturer / Supplier |
|-------|--|-------------------------|
| 1. | Olanzapine (API) | Gift Sample |
| 2. | Hydrochloric Acid | Rankem A Grade |
| 3. | Sodium Hydroxide | Rankem A Grade |
| 4. | Hydrogen Peroxide (H ₂ O ₂) | Rankem A Grade |

Table No- 1.2. List of Equipment's used for preparation of Olanzapine MDTs

| S. No. | Instruments / Glassware's | Manufacturer/ Supplier |
|--------|--|------------------------------|
| 1. | UV-visible double Beam Spectrophotometer | Schimadzu, Mumbai |
| 2. | Fourier Transmission Infra-Red Spectrophotometer | Agilent |
| 3. | Mechanical stirrer | Remi Elektrotech Ltd, Mumbai |
| 4. | Analytical Weighing Balance | Citizone |
| 5. | Digital Sonicator | Rivotek |
| 6. | Digital pH meter | Systronics, Delhi |
| 7. | Digital melting point apparatus | Perfit, Ambala cant |
| 8. | Magnetic stirrer | Remi Elektrotech Ltd, Mumbai |
| 9. | Volumetric Glass | Borosil A Grade |
| 10. | Measuring Cylinder | Borosil A Grade |

| | | |
|-----|------------------|-----------------|
| 11. | Graduate Pipette | Borosil A Grade |
| 12. | Bulb Pipette | Borosil A Grade |
| 13. | Glass Beaker | Borosil A Grade |
| 14. | Glass Road | Borosil A Grade |
| 15. | Funnel | Borosil A Grade |

METHODS:

1. IDENTIFICATION OF DRUG:-

A. Organoleptic Characteristics:-

The color, Odor, and taste of the drug were characterized and recorded.

B. Determination of Melting point:

The drug will be filled in one end fused Capillary tube and kept into digital melting point apparatus. The apparatus will operated and the temperature at which drug will start melting will be noted as melting point.

C. Determination The wavelength (λ_{\max}) of Olanzapine in 0.1 N HCl:-Standard stock solution of Olanzapine prepared by dissolving 50 mg of Olanzapine in 50 ml of 0.1 N HCl and sonicated for 15 minutes in bath Sonicator and prepares dilution of 1 mg/1 ml i.e. 1000 $\mu\text{g/ml}$ (1000 ppm) stock solution. From this stock solution prepared 10 $\mu\text{g/ml}$ solutions. Scan the sample at their standard λ_{\max} and determine the wavelength of Olanzapine

D. Preparation of standard plot of Olanzapine in 0.1 N HCl: -

Standard stock solution of Olanzapine will be prepared by dissolving 50 mg of Olanzapine in 50 ml of 0.1 N HCl and sonicated for 15 minutes in bath Sonicator and prepare dilution of 1 mg/1 ml i.e. 1000 $\mu\text{g/ml}$ (1000 ppm) stock solution. From this stock solution we can prepare

2-12 ppm solution, scan the sample at their standard λ_{\max} and prepared standard plot of olanzapine.

VALIDATION PARAMETER:

- 1. Accuracy:** The accuracy of an analytical method expresses the closeness of settlement between the fee which is usual either as a traditional proper fee or an standard reference price and the fee found. This is every so often termed trueness. The accuracy information is given in table.
- 2. Precision:** The precision of an analytical process expresses the closeness of settlement (degree of scatter) between a sequences of measurements acquired from more than one sampling of the equal homogeneous sample under the prescribed conditions. Precision may be considered at three levels: repeatability, intermediate precision and reproducibility. Precision be investigated using homogeneous, authentic samples. However, if it is no longer feasible to reap a homogeneous sample it might also be investigated the usage of artificially organized samples or

a sample solution. The precision of an analytical process is usually expressed as the variance, trendy deviation or coefficient of variant of a collection of measurements. The precision data are given in ta. Precision is similarly subdivided into two parts

a. Intra-day Precision:

Intra-day precision simply means within run which assesses precision during a single analytical run.

b. Inter-day precision

Inter-day precision simply means between-run which measures precision with time, and may involve different analysts, equipment, reagents, and laboratories.

3. Robustness/ Ruggedness

The definition for robustness/ruggedness applied is the robustness/ruggedness of an analytical procedure is a measure of its capacity to remain unaffected by small, but deliberate variations in method parameters and provides an indication of its reliability during normal usage. Robustness can be described as the ability to reproduce the (analytical) method in different laboratories or under different circumstances without the occurrence of unexpected differences in the obtained results, and a robustness test as an experimental set-up to evaluate the robustness of a method. The term ruggedness is frequently used as a synonym. Several definitions for robustness or ruggedness exist which are, however, all closely related.

4. Limit of Detection

LOD: The Limit of Detection (LOD) of an individual analytical procedure is the lowest amount of analyte in a sample, which can be detected but not necessarily quantitated as an exact value determined with statistical method by using Statistical formula. The limit of Detection (L.O.D.) was calculated as per below equation:

$$\text{Limit of Detection} = \frac{3.3 * S. D.}{\text{Slope}}$$

5. Limit of Quantitation

The Limit of quantification (LOQ) of an individual analytical procedure is the lowest amount of analyte in a sample, which can be quantitatively determined with statistical method by using statistical formula. The limit of Quantification (LOQ) was calculated as per below equation:

$$\text{Limit of Quantitation} = \frac{10.0 * S. D.}{\text{Slope}}$$

3. FORCE DEGRADATION STABILITY STUDY OF OLANZAPINE:**1. Hydrolytic degradation**

Hydrolytic degradation usually means the cleavage of chemical bonds by the addition of water. Generally, hydrolytic degradation or scarification is a step in the degradation of a substance. This can be performed in three conditions i.e. neutral medium, acidic medium and basic medium.

A. Hydrolytic Degradation of Olanzapine in Neutral Condition:

Accurately weighed 100 mg Olanzapine was taken in 100 ml volumetric flask. Then the volume was made with distilled water and refluxed for 3 Day at 60°C. The absorbance was measured in different hour by withdrawing the required amount of sample from the reaction mixture to prepare 12µg/ml concentration and subjected for UV analysis.

B. Hydrolytic Degradation of Olanzapine in Acidic Condition

Accurately weighed 100 mg Olanzapine was taken in 100 ml volumetric flask. Then the volume was made with 0.1N HCl and refluxed for 3 day at 60°C. Samples were withdrawn according to Protocol. From the drawn samples 12µg/ml solution were prepared and subjected for analysis. The representative UV-VIS spectrum indicates degradation after 1 day at 60°C.

C. Hydrolytic Degradation of Olanzapine in Basic Condition

Accurately weighed 100 mg Olanzapine was taken in 100 ml volumetric flask. Then the volume was made with 0.1N NaOH and refluxed for 3 day at 60°C. Samples were withdrawn according to protocol. From the drawn samples 12µg/ml solution were prepared and subjected for analysis. The representative UV-VIS spectrum indicates degradation after 1 day at 60°C.

2. Oxidative Degradation of Olanzapine

Accurately weighed 100 mg Olanzapine was taken in 100 ml volumetric flask. Then the volume was made with 3% H₂O₂ and refluxed for 3 day at 60°C.. Samples were withdrawn according to protocol. From the drawn samples 12µg/ml solution were prepared and subjected for analysis. The representative UV-VIS spectrum indicates degradation after 1 day at 60°C.

3. Thermal Degradation of Olanzapine

Accurately weighed 1000 mg Olanzapine was taken in a covered Petridis. Then the same was kept in an oven for 7 days at 60°C Then Samples were withdrawn according to protocol. From the drawn samples 12µg/ml solution were prepared and subjected for analysis. The representative UV-VIS spectrum indicates degradation after 7 days.

Table 1.3: Conditions for Forced Degradation Studies.

| Degradation Type | Experimental Conditions | Storage Conditions | Sampling Time (days) |
|-------------------|---|--------------------|----------------------|
| Hydrolysis | Control API (No acid or base) 0.1M HCl 0.1 M NaOH Acid control (No API) Base control (no API) | 40°C, 60°C | 1,3,5 |
| Oxidation | 3% H ₂ O ₂ (Peroxide) | 25°C, 60°C | 1,3,5 |
| Photolytic | Light 1 × ICH Light 2 × ICH Light 3 × ICH | NA | 1,3,5 |
| Thermal | Heat chamber | 60°C | 3,5,7 |

4. RESULT AND DISCUSSION:**1. IDENTIFICATION STUDY:-****A. Organoleptic Characteristics:-**

Table No. – 1.4: The Organoleptic Properties of Olanzapine as well as following,

| S.NO. | Organoleptic Properties | Result |
|-------|-------------------------|---------------------------|
| 1. | Color | Yellow crystalline Powder |
| 2. | Odor | Characteristics |
| 3. | Taste | Characteristics |

B. Determination of Melting Point

Melting point of Olanzapine was found to be $195.21 \pm 0.95^{\circ}\text{C}$ (Table 1.5). From the observation of the melting point, the drug can be considered to be sufficiently pure for employing it in present investigation. Melting point in Merck Index is $190-195^{\circ}\text{C}$.

Table No. 1.5: - Result of Melting Point Determination of Olanzapine.

| Observed Melting Point ($^{\circ}\text{C}$) | | | Mean \pm S.D. (n =3) |
|---|----------|----------|------------------------|
| Sample 1 | Sample 2 | Sample 3 | 195.21 \pm 0.95 |
| 194.66 | 195.40 | 195.58 | |

2. RESULT OF ANALYSIS:

A. Standard Curve of Olanzapine in 0.1 N HCl:-

The standard plots of Olanzapine were prepared in 0.1 N HCl. This indicates that the standard curve of Olanzapine in above media followed Beer law, R^2 values were found to be in between 1.0, the linear regression equation can be used of Olanzapine in 0.1 N HCl media.

Final Wavelength (λ_{max}) of Olanzapine is = 257 nm in 0.1N HCl Media

Table No 1.6:- Standard Plot of Olanzapine in 0.1 N HCl.

| S. No. | Concentration ($\mu\text{g/ml.}$) | Absorbance | | | Mean \pm S.D. |
|--------|--|------------|----------|----------|-----------------------|
| | | Sample 1 | Sample 2 | Sample 3 | |
| 1. | Blank | 0.0000 | 0.0000 | 0.0000 | 0.0000 \pm 0.0000 |
| 2. | 2.0 | 0.155 | 0.160 | 0.159 | 0.158 \pm 0.002 |
| 3. | 4.0 | 0.315 | 0.311 | 0.316 | 0.314 \pm 0.002 |
| 4. | 6.0 | 0.486 | 0.476 | 0.469 | 0.471 \pm 0.004 |
| 5. | 8.0 | 0.620 | 0.628 | 0.630 | 0.626 \pm 0.005 |
| 6. | 10.0 | 0.778 | 0.784 | 0.781 | 0.781 \pm 0.003 |
| 7. | 12.0 | 0.930 | 0.935 | 0.934 | 0.934 \pm 0.003 |




Figure 1: - Calibration Curve of Olanzapine.

Table No. 1.7:- Regression equation and correlation coefficient of Olanzapine in 0.1 N HCl.

| S. No | Media | Regression Equation | Correlation Coefficient (R^2) |
|-------|-----------|-----------------------|-----------------------------------|
| 1. | 0.1 N HCl | $Y = 0.0779x + 0.002$ | 1.0 |

VALIDATION RESULTS OF OLANZAPINE:**1. ACCURACY:**

Table 1.8: Accuracy Data of the UV-VIS Spectrophotometric Method for Olanzapine

| Sample | Concentration (µg/ml.) | | Absorbance | % Recovery | Statistical Analysis |
|------------------------|------------------------|---------------------|------------|------------|--|
| | Pure Concentration | Final Concentration | | | |
| SMP ₁ :80% | 8 | 10 | 0.611 | 97.72 | Mean:-98.52 S.D.- 0.73 % RSD- 0.74 |
| SMP ₂ :80% | 8 | 10 | 0.620 | 99.16 | |
| SMP ₃ :80% | 8 | 10 | 0.617 | 98.68 | |
| SMP ₄ :100% | 10 | 10 | 0.780 | 99.87 | Mean:-99.22 S.D.- 1.45 % RSD- 1.46 |
| SMP ₅ :100% | 10 | 10 | 0.762 | 99.56 | |
| SMP ₆ :100% | 10 | 10 | 0.783 | 100.25 | |
| SMP ₇ :120% | 12 | 10 | 0.928 | 99.05 | Mean:-99.44 S.D.- 0.50 % RSD- 0.51 |
| SMP ₈ :120% | 12 | 10 | 0.937 | 100.02 | |
| SMP ₉ :120% | 12 | 10 | 0.930 | 99.27 | |

2. PRECISION:**(a.) Repeatability:****Table 1.9:** Precision Data Showing Repeatability of the UV-VIS Spectrophotometric Method for Olanzapine.

| S.No. | Concentration (µg/ml.) | Absorbance | Calculated Amount (µg/ml.) | Statistical Analysis |
|-------|---------------------------|------------|-------------------------------|---|
| 1. | 10 | 0.788 | 10.08 | Mean:- 10.06 S.D.- 0.067 % RSD- 0.67 |
| 2. | 10 | 0.780 | 9.98 | |
| 3. | 10 | 0.786 | 10.06 | |
| 4. | 10 | 0.781 | 10.0 | |
| 5. | 10 | 0.790 | 10.11 | |
| 6. | 10 | 0.794 | 10.16 | |

(b.) Intraday Precision:**Table 1.10:** Intra Day Precision Data of the UV-VIS Spectrophotometric Method for Olanzapine

| Concentration (µg/ml.) | Sample-1 (Abs.) | Sample-2 (Abs.) | Sample-3 (Abs.) | Statistical Analysis |
|---------------------------|--------------------|--------------------|--------------------|--|
| 10 | 0.782 | 0.783 | 0.782 | Mean:- 10.02 S.D.- 0.01 % RSD- 0.09 |
| 10 | 0.790 | 0.779 | 0.785 | |
| 10 | 0.780 | 0.782 | 0.779 | |
| 10 | 0.776 | 0.786 | 0.787 | |
| 10 | 0.788 | 0.790 | 0.785 | |
| 10 | 0.784 | 0.781 | 0.791 | |
| MEAN | 0.783 | 0.782 | 0.784 | |
| Cal. Amount (µg/ml.) | 10.02 | 10.01 | 10.03 | |

(c.) Interday Precision:

Table 1.11: Inter Day Precision Data of the UV-VIS Spectrophotometric Method for Olanzapine

| Concentration (µg/ml.) | Sample (Abs.) (Day-1) | Sample (Abs.) (Day-2) | Sample (Abs.) (Day-3) | Statistical Analysis |
|---------------------------|--------------------------|--------------------------|--------------------------|--|
| 10 | 0.783 | 0.787 | 0.774 | Mean:- 10.0 S.D.- 0.020 % RSD- 0.20 |
| 10 | 0.787 | 0.780 | 0.785 | |
| 10 | 0.792 | 0.790 | 0.778 | |
| 10 | 0.790 | 0.783 | 0.784 | |
| 10 | 0.781 | 0.780 | 0.775 | |
| 10 | 0.776 | 0.776 | 0.789 | |
| MEAN | 0.784 | 0.782 | 0.780 | |
| Cal. Amount (µg/ml.) | 10.03 | 10.01 | 9.98 | |

3. Ruggedness Data:**Table 1.12:** Ruggedness Data of the UV-VIS Spectrophotometric Method by Different Analyst for Olanzapine.

| Analyst-1 | | | | Analyst-2 | | | |
|-------------------------------|-------|-----------------------|--|-------------------------------|-------|--------------------------|--|
| Conc ⁿ (µg/ml.) | Abs. | Cal. Amt. (µg/ml.) | Statistical Analysis | Conc ⁿ (µg/ml.) | Abs. | Cal. Amt. (µg/ml.) | Statistical Analysis |
| 10 | 0.792 | 10.14 | Mean:- 10.5 S.D.- 0.061 % RSD- 0.61 | 10 | 0.786 | 10.06 | Mean:- 10.0 S.D.- 0.020 % RSD- 0.20 |
| 10 | 0.785 | 10.05 | | 10 | 0.778 | 9.96 | |
| 10 | 0.789 | 10.10 | | 10 | 0.784 | 10.03 | |
| 10 | 0.784 | 10.03 | | 10 | 0.790 | 10.11 | |
| 10 | 0.779 | 9.97 | | 10 | 0.787 | 10.07 | |
| 10 | 0.782 | 10.01 | | 10 | 0.783 | 10.02 | |

4. Robustness Data:**Table 1.13:** Robustness Data of the UV-VIS Spectrophotometric Method by Different Analyst for Olanzapine.

| WATER: HCl (90:10) | | | | WATER: HCl (85:15) | | | |
|-------------------------------|-------|--------------------------|---|-------------------------------|-------|--------------------------|--|
| Conc ⁿ (µg/ml.) | Abs. | Cal. Amt. (µg/ml.) | Statistical Analysis | Conc ⁿ (µg/ml.) | Abs. | Cal. Amt. (µg/ml.) | Statistical Analysis |
| 10 | 0.774 | 9.91 | Mean:- 10.01 S.D.- 0.08 % RSD- 0.80 | 10 | 0.783 | 10.02 | Mean:- 10.01 S.D.- 0.072 % RSD- 0.72 |
| 10 | 0.786 | 10.06 | | 10 | 0.775 | 9.92 | |
| 10 | 0.776 | 9.93 | | 10 | 0.788 | 10.08 | |
| 10 | 0.790 | 10.11 | | 10 | 0.781 | 10.0 | |
| 10 | 0.787 | 10.07 | | 10 | 0.777 | 9.94 | |
| 10 | 0.784 | 10.03 | | 10 | 0.789 | 10.10 | |

5. Limit of Detection (LOD) & Limit of Quantitation (LOQ): -**Table 1.14:** Limit of detection and Limit of quantitation of Olanzapine by UV-VIS Spectrophotometric Method.

| S.No. | Parameter | Standard Deviation | Slope | Formula | Calculation (µg/ml.) |
|-------|--------------------------------|-----------------------|--------|----------------------|-------------------------|
| 1. | Limit of Detection (LOD) | 0.009 | 0.0779 | $3.3 * (S.D./Slope)$ | 0.381 |
| 2. | Limit of Quantitation (LOQ) | 0.009 | 0.0779 | $10 * (S.D./Slope)$ | 1.15 |

FORCE DEGRADATION STABILITY STUDY OF OLANZAPINE**1. Hydrolytic Degradation of Olanzapine:****(A.) Hydrolytic Degradation of Olanzapine in Neutral Condition:****Table 1.15:** Hydrolytic Degradation of Olanzapine in Neutral Condition..

| S.NO. | Name | Absorbance | Concentration (µg/ml.) | % Degradation |
|-------|---------------|------------|------------------------|---------------|
| 1. | Olanzapine | 0.937 | 12.0 | 0 |
| 2. | Degradation-1 | 0.684 | 8.75 | 27.04 |
| 3. | Degradation-2 | 0.523 | 6.68 | 44.26 |
| 4. | Degradation-3 | 0.486 | 6.21 | 48.22 |
| 5. | Degradation-4 | 0.412 | 5.26 | 56.14 |

(B.) Hydrolytic Degradation of Olanzapine in Acidic Condition:**Table 1.16:** Hydrolytic Degradation of Olanzapine in Acidic Condition..

| S.NO. | Name | Absorbance | Concentration (µg/ml.) | % Degradation |
|-------|---------------|------------|------------------------|---------------|
| 1. | Olanzapine | 0.937 | 12.0 | 0 |
| 2. | Degradation-1 | 0.511 | 6.53 | 45.0 |
| 3. | Degradation-2 | 0.429 | 5.48 | 54.32 |
| 4. | Degradation-3 | 0.386 | 4.92 | 58.92 |

(C.) Hydrolytic Degradation of Olanzapine in Basic Condition:**Table 1.17:** Hydrolytic Degradation of Olanzapine in Basic Condition.

| S.NO. | Name | Absorbance | Concentration (µg/ml.) | % Degradation |
|-------|---------------|------------|------------------------|---------------|
| 1. | Olanzapine | 0.937 | 12.0 | 0 |
| 2. | Degradation-1 | 0.503 | 6.43 | 46.40 |
| 3. | Degradation-2 | 0.317 | 4.04 | 66.30 |
| 4. | Degradation-3 | 0.245 | 3.11 | 74.0 |

2. Oxidative Degradation of Olanzapine:**Table 1.18:** Oxidative Degradation of Olanzapine.

| S.NO. | Name | Absorbance | Concentration (µg/ml.) | % Degradation |
|-------|---------------|------------|------------------------|---------------|
| 1. | Olanzapine | 0.937 | 12.0 | 0 |
| 2. | Degradation-1 | 0.782 | 10.01 | 16.55 |
| 3. | Degradation-2 | 0.573 | 7.32 | 38.91 |
| 4. | Degradation-3 | 0.285 | 3.63 | 69.72 |

3. Thermal Degradation of Olanzapine:**Table 1.19:** Thermal Degradation of Olanzapine.

| S.NO. | Name | Absorbance | Concentration (µg/ml.) | % Degradation |
|-------|---------------|------------|------------------------|---------------|
| 1. | Olanzapine | 0.937 | 12.0 | 0 |
| 2. | Degradation-1 | 0.803 | 10.28 | 14.31 |

CONCLUSION:

The proposed technique was simple, sensitive and reliable with accurate precision and accuracy. This approach is precise while estimating the business method barring interference of excipients and the different additives. Hence, it can be used for routine determination of Olanzapine in bulk sample. The proposed technique for Force degradation balance study indicates that there is considerable degradation located in stress condition.

ACKNOWLEDGEMENT:

Vipin Kumar Tomar (Sr. Manager, Quality Control) would like to acknowledge the support during this research article from, Psychotropic India Limited, Haridwar (U.K.), for its esteemed support and encouragement for their support and continuous encouragement and for providing the necessary facilities.

REFERENCES

- [1] Burton ME, Shaw LM, Schentag JJ, Evans WE, 2005, Applied Pharmacokinetics & Pharmacodynamics. Principles of Therapeutic Drug Monitoring, 4th ed. Lippincott Williams & Wilkins, pp. 815.
- [2] International Conference on Harmonization, guidelines Q1A and Q1F, www.ich.org
- [3] Glazer W, 1997, Extra pyramidal side effects, tardive dyskinesia and the concept of atypicality, J Clin Psychiatry; pp. 18-21.
- [4] Firdous S, Aman T, Nisa AU. 2005, Determination of Olanzapine by UV Spectrophotometry and Non-aqueous Titration, J Chem Soc Pak; 27(2): pp.163 – 67,
- [5] Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B, 2001, Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia. A review and meta-analysis of randomized trials, pp.518–526, Am J Psychiatry.
- [6] International Conference on Harmonization (ICH), Q2b: 1997, Validation of Analytical Procedures: Methodology, US FDA Federal Register, Vol. 62, pp. 27463.
- [7] Stenlake JB, Beckett AH, 2007, The Basis of Spectrophotometry. Practical pharmaceutical Chemistry, 4th ed. Part.2, New Delhi: CBS Publishers and Distributors, pp. 255-7.
- [8] Singh JK, 2007, Degradation study of cardiovascular drugs, Anal Chem, pp. 10:401.
- [9] Skoog DA, Holler FJ, Crouch SR, 2007, An Introduction to Ultraviolet- Visible Molecular Absorption Spectrometry. In, Principles of Instrumental Analysis, 6th edition. Thomson Reuter, pp. 336.
- [10] Singh S, Bakshi M, 2000, Stress test to determine inherent stability of drugs, Pharm Technol 4; pp. 1-14.
- [11] Singh S, Junwal M, Modhe G, Tiwari H, Kurmi M, et al., 2013, Forced degradation studies to assess the stability of drugs and products, TRAC Trends in Analytical Chemistry 49: pp. 71-88.
- [12] Marin A, Barbas C, 2013, LC/MS for the degradation profiling of cough-cold products under forced conditions, Journal of Pharmaceutical and Biomedical Analysis 35: pp. 1035-1045.
- [13] Brümmer DH, 2011, How to approach a forced degradation study. Technical Bulletin. Life Science, pp. 31.
- [14] Singh R, Rehman ZU, 2102, Current trends in forced degradation study for pharmaceutical product development, Journal of Pharmaceutical Education and Research, pp. 54.
- [15] Naveed S, Shafiq A, Khan M, Jamal M, Zafar H, et al., 2014, Degradation Study of Available Brands of Metformin in Karachi Using UV Spectrophotometer, J Diabetes Metabolism, pp. 328.
- [16] Naveed S, Naseem Y, Samie S, Khan S, Siddiqui S, et al., 2014, Degradation study of five different brands of ciprofloxacin using UV-visible spectrophotometer and their comparative study, IRJP, pp. 189-190.
- [17] Gaur A, Mariappan TT, Bhutani H, Singh S., 2005, A Possible Reason for the Generation of Out-of-Trend Stability Results: Variable Air Velocity at Different Locations within the Stability Chamber, Pharm. Technol, 29, pp. 46-49.
- [18] Kommanaboyina B., Rhodes CT, 1999, Trends in stability testing, with Emphasis on Stability during Distribution and Storage, Drug Dev.Ind. Pharm, pp. 57-867.
- [19] Gabriel K. Kaddu, 2009, Stability Studies -World Health Organization, pp. 38.
- [20] ICH Q1A, “Stability Testing of New Drug Substances and Products” <http://www.ich.org/LOB/media/MEDIA419.pdf>